The topical calcineurin inhibitors tacrolimus and pimecrolimus are useful and effective anti-inflammatory immunomodulator adjuncts in managing atopic dermatitis (AD). Unfortunately, because of the increased risk of lymphoma in transplant recipients receiving systemic tacrolimus and because of malignant neoplasms in animal studies with pimecrolimus, their use as topical agents has raised concerns.1 Yet the topical use of these drugs in humans since the mid-1990s has not appeared to cause any clear immunosuppressive propensity toward malignancy.
Hanifin JM. A Reassuring Rejoinder Against Malignant Influences of Topical Calcineurin Use in Children. JAMA Dermatol. 2015;151(6):587–588. doi:10.1001/jamadermatol.2014.4306
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: